嚢胞性線維症の診療の手引き【改訂2版】.indd
|
|
- えりか ひめい
- 5 years ago
- Views:
Transcription
1 2
2 CFTR
3 2
4
5 CF 2015 CFTR , CFTR
6 2018 1
7
8 2018 1
9
10 ,
11
12 1 1 3 CFTR 5 A 7 B 11 C 11 CFTR A B 25 C 27 D 29 E 31 F 33 G A 41 B CF A 53 B 55 C 57 A 59 B 61 C 63 D 65
13 A TOBI B 5 85 C A 91 B 91 C 93 A CF 95 B CF 97 C 98 D CF
14 cystic fibrosis transmembrane conductance regulator CFTR CFTR 2CFTR CFTR CF CFTR CFTR CFTR CF CFTR CF 1 CFTR CFTR CF 30 CFTR CF
15 CFTR
16 3, ,000, , ,
17 % % % % %
18 5 CF CFTR Cystic FT R CF 1983CF CF CFTR ABC CFTR CFTR 1 CFTR CFTR A CFTR R A CFTR CFTR 3 CFTR CFTR CFTR
19 2 1CFTR CFTR 2CFTR SLC26 SLC26 CFTR CFTR R 6
20 A CFTR CFTR + 1 CFTRCFTR CO
21 2 1 ASL CFTR 8
22
23 2 HCO 3 - HCO 3 - HCO 3 - HCO 3 - HCO - 3 HCO - HCO HCO 3 - HCO 3 - HCO 3 - H + +HCO - 3 H2 CO 3 Ca 2+ +HCO - 3 CaHCO3 + +CaCO3 HCO 3 - HCO 3 - Cl - HCO 3 - Cl - HCO 3-2HCO3 10
24 B 3 CFTR CFTR 3 C + 2 CFTR 1 + CFTRCFTR CFCFTR CF
25 2 1 2Cl Cl 110 mmol/lcl CFTR 40 mmol/l CF Cl 60 mmol/l12
26 CFCFTR 7 27 CFTR CF CF 2,000 CFTR1, CFTR2 CFTR 1 CFTR2 CFTR CF F50856,000 CF 70% 2 3% CF CFTR CF 27 CF CFTR CFTR 16 1 CF 2/3 CFTR CFTR CF CF 13
27 2 1 CF 27CFTR dele16 17b 6 T1086I 4 Q98R 3 M152R 3 L441P del10 3 E217G 2 R347H 2 H1085R 2 Q1352H 2 460insAT 1 R75X 1 G85R 1 E267V 1 F508 1 L548Q 1 I556V 1 L571S 1 T663P delA 1 D924N 1 V1318I 1 R1453W 1 5T 1 125C CFTR 1 XV 2830, CFTR1, CFTR2 3 14
28 CF 2007CF CFTR 25 CF 1 CF CFTR 11 CFTR CFTR1 CF CF C CFTR 14 CF
29 2 1CFCFTR Cl mmol/l 1 38 M / T1086I dele16 17b F / 1609delCA G542X M / dele16 17b ND * M / R75X dele16 17b M / E217G ND ** F / dele16 17b dele16 17b F / L441P ND F / 182delT F508del F / F508del dele16 17b M / R1066C R1066C F / F508del Q1042fs M / 1540del10 Y517H M / Y563H H1085R F / R347H dele16 17b F / L441P H1085R M / dele2 3 dele16 17b F / F508del S945L > M / F508del F508del F / R75X R347H M / dele16 17b dele16 17b M / ND ND M / L441P L441P M / E474X I1315fs 24 5 M / c.744 3C>G dele16 17b F / dele16 17b dele16 17b * exon1cftr ** CFTR 16
30 dele legacy name protein name cdna name dele16 17a 17b c _ dele16 17b del L441P 1 p.leu441pro c.1322t>c 4 R75X p.arg75x c.223c>t 2 R347H p.arg347his 4 c.1040g>a 2 H1085R p.his1085arg c.3254a>g 2 c _ del E217G p.glu217gly c.650a>g 1 c.744 3C>G del10 2 p.met470glufsx54 6 c.1408_1447del ATGATTATGG 2 Y517H 1 p.tyr517his c.1549t>c 1 Y563H 1 p.tyr563his c.1687t>c 1 Q1042fs 1 p.glu1042fs 6 c.3123_3124insa 1 T1086I p.thr1086ile c.3257c>t 1 deltaf508 p.phe508del c.1521_1523delctt 6 R1066C p.arg1066cys c.3196c>t 2 182delT 2 p.phe17serfsx8 6 c.50delt 2 1 E474X 1 p.glu474ter 7 c.1420g>t delCA 2 p.gln493valfsx10 6 c.1477_1478delca G542X p.gly542x c.1624g>t 1 S945L p.ser945leu c.2834c>t 1 I1315fs 1 p.ile1315fs 6 c.3944_3951del TATGGAAA 1 1legacy name 2CFTR 1 Met A c.1 3 c.2098 cdnaexon cdnaexon17b exon exon17b bp GA CFTR347 5 exon21760bp exon410222bp18185bp 6 fs 7 XTer
31 2 1 CF 25CF 18
32 BT CFTR CFTR2 CF CFTR CF
33 CFTR 2 A BCl CCFTR Definite CFTR Probable CFTR Definite Probable 20
34 A CF 1953CF + CF CF 1989 CF CFTR CF CFTR CF 5 30 CF + K + 21
35 2 1 Wescor Macroduct Sweat Collection System 2007 CF Na + Cl 60 meq/l 40 meq/l 90 meq/l 60 meq/l meq/l meq/l
36 CFCFTR CF CFTR CF CFTR CF CF 3 CF
37 Cl 1 CF CL g cm 2 min 1 g cm 2 min 1 Cl M
38 B CFTR 3 1 CFTR~5% CF BT PABA BT
39 2 1 A6 B %90% 2 3 BT PABA BT PABA 6 PABA >70% 3 26
40 C CF CF 95% CF CF 8 CF % X
41 FCT 28
42 D CF Cystic 1 10 CF 1 CF CF 1 KARGER 29
43 2 1Cystic Fibrosis Foundation CF 30
44 E CF CFTR CF 1 CF CF 5 10% CT, MRI CT CF
45 2 HE10 1 CF CFLD A B
46 F CF X T 4 33
47
48 G 1989 CF CFTR 2000 CFTR 2 1 / CFTR MLPA C1 CFTR CF CF CF CF CF CF CF 35
49 2 ex16 ex17a ex17b ex16 ex17a ex17b ex16 ex17a ex17b 1 dele16 17b CFTR CF CF CF CF CFTR 1CFTR1, CFTR2 2 CFTR
50 CFTR CFTR CF CF 1 CF 0 CF RT 1 2dele16 17b0 2 3 c.744 3C>G 5 CFTR 3 RT 4 C G 4 37
51 2 1 1RT PCRexon16,17a,17b 22 exon1 CFTR exon GU GU YNCURAC YNY AG exon 3 i n t r o n Y: C,U R: A,G N: A,C,G,U 3 Pre mrna GU AG 5'GU 3'YAG A 38
52 CFTR 4E217G20 RT CFTR5, 1 CF 5 CF38 CF 4 CFTR CFTR CFTRexon1 5 exon4 7 exon1 5 exon4 7 P P C exon1 5 exon4 7 RT PCR AQP5 RNA 25 CFTR exon1 5 exon4 7 exon1 5 exon4 7 P C
53 2 (a) (b) exon6a exon6b exon6a exon6b 43 c.744 3C>Gexon6b 54 CFTRRT PCR 65 CFTR RT PCR 40
54 A CF 1 6 CF 1%FEV1 1 / %FEV1 > 90% 70 89% 40 69%< 40% 6 6CF %FEV1 1 1 X ~3 3 CT %FEV1 2 5 CF 41
55 2 1 CF %FEV Canadian Cystic Fibrosis Patient Data Registry CPDR Report Brody CT score Wisconsin score%fev1 1 2 CFF
56 B CF CF CF
57 2 g/dl) BMI R² = BMI * *P<0.05 signi cant correla on g/dl) BMI R² = BMI * *P<0.01 signi cant correla on 1 CF 18 p BMI 18 BMI p50 22 p25 p % p10 p p
58 / 2 / / / 3 4/
59
60
61 2 48
62 Cl - Cl Pseudomonas aeruginosa Staphylococcus aureus MSSA MRSA Haemophilus influenzae g/dl g/dl 1 90% 70% 89% 40% 69% 40% 49
63 / / CF (Cl - ) mmol/l mmol/l mmol/l 200μg/g >200μg/g 200μg/g >200μg/g + + 2CF CF CF Cl 50
64 CF CF CF 51
65
66 A CFTR 3 CFTR CF CFTR 1 CFTR CFTR 3 CFTR CFTR1 CFTR TG TG 12 3 CFTR CF
67 2 1Cl 1 CFTR n=140 n=36 n=360 E217G Exon 6a 3 2.1% 0 0% 6 1.7% M470V Exon % % % I556V Exon % 0 0% % L1156F Exon % * 1 2.8% 2 0.6% Q1352H Exon % * 1 2.8% 7 1.9% R1453W Exon % % * 7 1.9% *:p<0.01 vs. NS by Yates Chi square test 2 CFTR Genotype 54
68 B 1 CF CF B % 6 CFTR CFTR % 2 CFTR CFTR TG 5T 5CFTR 5TTG CFTR CF 3 CFTR 55
69 2 1 DPB
70 C Congenital bilateral absence of the vas deferens CBAVD CBAVD 1 6%1 2% CF 95% CBAVD CF CBAVD CF CFTR 1 CBAVD CF CFTRCFTR CFTR CBAVD CFTR CFTR 8 3 TG TG T5 T7 T9 TGT 9 CFTR CBAVD CFTR 27CBAVD CFTR 7 5T T5 11 CBAVD CFTR 47%11 58%1 CFTR53 3 CFTR5T T5 1 CBAVD CFTR
71 2 1 CF vas deferens CBAVD CFTR 2 No CFTR TG mtn 1 41 G1349S/Q1352H TG 11T7/ TG 11T W216X/Q1352H TG 11T7/ TG 11T Q1352H/*WT TG 11T7/ TG 13T Q1352H/WT TG 11T7/ TG 13T Q1352H/WT TG 11T7/ TG 13T WT/WT TG 13T5/ TG 13T WT/WT TG 13T5/ TG 13T WT/WT TG 13T5/ TG 12T WT/WT TG 13T5/ TG 12T WT/WT TG 13T5/ TG 11T WT/WT TG 12T5/ TG 12T WT/WT TG 12T7/ TG 12T WT/WT TG 12T7/ TG 12T WT/WT TG 12T7/ TG 12T WT/WT TG 12T7/ TG 12T WT/WT TG 12T7/ TG 12T WT/WT TG 12T7/ TG 11T WT/WT TG 11T7/ TG 11T WT/WT TG 11T7/ TG 11T7 58
72 A CF CF CF A B X CT CF 1 70 CF 3 CF
73 2 2 1 XCT X CT Torr 2 CT 60
74 B 2 75% ,,,
75 2 CT CT 3 62
76 C 90 SBDS 90 1 CT 2 SBDS CFTR CF CF G 63
77 2 Shwachman Diamond syndrome
78 D 30 CF 1 CF % 33% % 74% 10% 1% 2 CF CFTR CF CFTR CF CF
79 2 1 2 Genetic PRSS1 SPINK1 CFTR CTRC Autoimmune Obstructive Pancreas divisum Sphincter of Oddi dysfunction Gallstones Pancreatic duct malunion Pancreatic duct obstruction Other Toxic/metabolic Alcohol Passive smoking Hyperlipidemia Medication Metabolic disease Other None cited 67% 43% 19% 14% 3% 4% 33% 20% 1% 4% 3% 1% 7% 11% 1% 4% 1% 1% 1% 1% 11% The total exceeds 100%, because some children have more than 1 factor % % % % 5 2.0% 4 1.6% 2 0.8% 2 0.8% %
80 A 1 CF CF 20 50% CF 67
81 2 Flume PA, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care.2009;54:
82 1 CFTR FEV
83 2 1 Kaplan Meier 2.5mg 2 # Kaplan Meier 2.5mg # FEV 1 FVC10 11 X
84 TOBI CF TOBI TOBI 3 8 CF FDA TOBI
85 2 1TOBI 2 TOBI Inhaled Powder Podhaler 72
86 TOBI CF CF 73
87
88 1 1, , 3 75
89
90 ACBTAD 1 1 DVD
91 2 S1 3 S9 1 78
92 2 CF 2017CF CF CF ,000 / 79
93 2 1 BMI μg/g 1 mg SD 1.5 SD SD 0.5 SD ,4 SD 0.8 SD , SD 0.1 SD SD 0.8 SD SD 1.4 SD SD 2.1 SD < , SD 0.4 SD , SD 1.2 SD SD 1.2 SD SD 1.7 SD SD 1.4 SD SD 2.0 SD HCO 3- CFTR HCO 3- EN ph fibrosing colonopathy 1 80
94 3 CFTR
95 2 1 CF 18 p BMI 18 BMI p50 22 p25 p % p10 p p CF A D 25 OH D E 3 CF MCT A D E K BMI 82
96 4 CF CF K B CF
97 2 IVR* TIPS* ARB* EVL*,EIS* IVR* S-B* B-RTO*,PTO*,TIO* Hassab * IVR* PSE* * IVR: interventional radiology, TIPS: transjugular intrahepatic portosystemic shunt, EVL: endoscopic vraiceal ligation, EIS: endoscopic injection sclerotherapy, S B : Sengstaken Blakemore Tube, B RTO: balloon occluded retrograde transvenous obliteration, PTO:percutaneous transhepatic obliteration, TIO: trans ileocolic obliteration, Hassab :, PSE: partial splenic embolization, ARB: 84
98 B 5 CF CF % 1 A 48% CF B % A 1 2 B % % 4 CF 28% 12% 1 85
99 2 1 13/25 9/25 lactam 1 tobramycin 9 tetracycline 1 macrolide 12 sulfamethoxazole/trimethoprim /25 6/25 1/25 ambroxol hydrochloride 4 tulobuterol 2 montelukast sodium 1 bromhexine 8 theophylline 1 macrolide 1 procaterol 3 15/25 5/25 2/25 Dornase alfa 14 procaterol 3 budesonide 1 bromhexine 2 formoterol 1 fluticasone 1 N acetyl L cysteine 1 vilanterol 1 tiotropium / /25 7/25 EN 3/25 4 9/
100 C CF CF % CF CF
101 factbook 88
102 CFTR CFTR G551D G1349D 8 CF 1 2 F508 F508 CF FEV 1 FDA 1 CFTR CFTR FEV
103 2 Ivaca or Lumaca or 1 Ivacaftor Lumacaftor Cl FEV 1 BMI Ivacaftor Phase II 2010 STRIVE 2011 ENVISION 2013 KONNECTION 2014 KONDUCT 2015 DISCOVER 2012 G551D 59.5 mmol/l NS NA G551D 48.1 mmol/l 10.5% 2.7 kg G551D 53.5 mmol/l 10.0% 2.8 kg non G551D G178R, S549N, G551S, G1244E, S1251N, S1255P, G1349D 49.2 mmol/l 10.7% 0.7 kg R117H 23.9 mmol/l 5.0% NS F508homo 2.9 mmol/l NS NS Lumacaftor Phase II 2012 F508homo 8.21 mmol/l NS NS Lumacaftor/ lvacaftor Phase II 2014 TRAFFIC 2015 TRANSPORT 2015 F508homo NS 7.7% NA F508homo NA 2.6% NS F508homo NA 3.0% 0.36 kg/m 2 90
104 A 7 CFTR 2, , CFTR 25 CFTR27 1, CFTR A342 B CFTR 91
105 2 1 2 CFTR
106 C CF A A 2A A CF CF CF 93
107 CF 2 94
108 A CF CF 2011 CF CF CF 2012 CF CFTR 1 1 CF
109 96 2 CF CFTR 1CF 2CF CF
110 B CF CF CF CF CF , ,000 97
111 2 C 98
112 D CFCF 1955CF CF CF CF CF CF CF CF CF CF CF CF CF CF 99
113 2 CF Trust CF Foundation 100
114 / ABG RA 101
115 2 CF X CT F
116 9X 14X 17X 103
117 2 14 CT mucoid impaction 104
118 / C 8 14 C C CFTR I502X / Q542X 105
119 2 1 A, B 1 X P C 1CT D 2 CT 106
120 IGF 1 < 7 IGF 1 FEV1% 3 107
121 2 A (cm/ ) B C 1 A AB SD. C A B C 2CT A B 7 10C
122 X
123 microcolon CF Cystic CF CF 3 110
124 % CT
125 2 1 1 Creon 6g Pulmozyme dornase alfa 2.5mg 5% 3 4 Creon Pulmozyme IPV mg 2 150mg 200mg 2 180mg 270mg g 3g 3 180mg 360mg CT 112
126 5 CF 2 2 3CT CF CFTR CF 2 3 CT CF 1 6CF CF
127 2 1CT consolidation 2 6CT
128 CF CF CF
129 2 1 2 ( ) 1988 (12Yrs) 1994 (18Yrs) 1999 (23Yrs) 1999 (23Yrs) 2001 (25Yrs) 2002 (26Yrs) 2007 (31Yrs) 116
130 X 7 C T 117
131 CT CT 118
132
133 consolidation
134 K CF CF CF
135 2 WBC 12.9X10 3 / I TP 6.9 g/dl ph RBC 504X10 4 / I Alb 4.3 g/dl pco mmhg Hb 13.6 g/dl Na 115 meq/l HCO mmol/l Hct 37.6 % K 2.3 meq/l BE 19.9 mmol/l PLT 59.8X10 4 / I Cl 57 meq/l U Na <20 meq/l AST 65 IU/l Ca 11.5 mg/dl U K 16.2 meq/l ALT 31 IU/l BUN 7.9 mg/dl U CI <20 meq/l LDH 256 IU/l Cre 0.28 mg/dl U Cre mg/dl CRP 0.1 mg/dl 122
136 9 Cystic fibrosis CF 2 CF CT CF CF , K CF 123
137 CT CF 2 1 CFTR 2CF
138
139 ,0001, FAX
140 ISBN C E 定価 : 本体 1852 円 + 税
(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
More information/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1
11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1
More information21 5 I C T J-Doit High risk Risk 20 7 21 34,324 30,858 38,735 26,800 27,490 20,472 18,533 20,096 14,913 14,931 488 470 491 435 446 10 t-pa intervention t-pa interventionclipping simulator subspecialty
More information125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
More informationuntitled
Metabolic syndrome,,,, 81 81 , 17 17 2 Lung Ca non small cell carcinoma / / food( food( ) drug( drug( ) 100mg 750mg WBC 5510/ l RBC 483 / l Hb 10.3g/dl, Ht 42.0% Plt 19.0 / l TP 8.1g/dl Alb 4.6g/dl Glb
More informationBUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
More information日本呼吸器学会雑誌第47巻第6号
Fig.1 A,ChestX-rayfilm demonstratingatumorshadow intherightlowerlungfield.b,chestct scan demonstratingtherightmiddlelobemass,measuring9.0 7.3cm.C,AbdominalCT scanshowingfree airintheabdominalcavityanddirtyfatsignaroundthesigmoidcolontumor.
More information日本呼吸器学会雑誌第44巻第6号
Aspergillus β Table1 Laboratoryfindingsonadmission Hematology WB Seg Band Lymph Eos Baso RB Hb Hct Plt Biochemistry AST ALT LD ALP γ-gtp K 17,700 /mm 3 70.0 % 7.0 % 17.0 % 2.0 % 1.0 % 337 10 4 /mm 3 11.5g/dl
More information全国循環器撮影研究会 HP講座No
HP No.6 4 HP No.6 4 NTT 1. 1936 1953 Seldinger Seldinger 1956 Odman X Interventional Radiology IVR 1967 Margulis 1964 Dotter 2. 2.1 IVR CT MR IVR 2.2-1 - HP No.6 4 2.3 feeding artery parasitic supply increased
More informationsick contact1l
Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5
More informationuntitled
1 ... 3... 3... 3... 4...13...16...18...20...22 2 PTPE 3 PTPE CT Grade 2 A PTPE PTPE 4 A S 3 3 B H3,P1,N1,M1, LM0, R23 15 20gS, ptype 3, 60 x 50mm, pt4b/siurinary bladder, int, INF, ly2, v1, ppm070mm,
More information日本呼吸器学会雑誌第44巻第10号
β Table1 Laboratoryfindingsonthefirstvisit Hematology WBC Neut. Lyn. Mon. Eos. Bas. RBC Hb Ht Plate 5,650 /μl 79.2 % 14.9 % 3.9 % 1.8 % 0.2 % 418 10 4 /μl 12.5g/dl 38.4 % 21.2 10 4 /μl Serology CRP IgG
More information_02三浦.indd
36, 7-11, 2016 IPD PCV 5 3 80% 1 invasive pneumococcal disease ; IPD 2010 7 PCV7 2013 13 PCV13 IPD IPD 2,3 2015 1 2015 12 5 1 IPD 2015 1 12 IPD 5 IPD 1 4 2 5 http://pneumocatch.jp/ 5 Statens Serum Institut
More informationWBC 5700 / l Gran 58.5% Lym 29.0% Eosin 0.3% RBC 499x10 6 / l Hb 14.8 g/dl Hct 44.40% PLT 15.3x10 3 / l PT 157% Fbg 616 mg/dl DD 0.99 g/ml GOT GPT LDH
54 2002 3 1992 2002 3 2002 7 2004 1 15 4Kg74.0Kg 1 24 80.6 kg BUN 26.0mg/dl, s-cr 2.3mg/dl, 3+ 1 27 40 /34 174.3 cm 80.6 kg 1 10kg36.8 120/70 mmhg 88 / 14 / fibrinogen 616 mg/dl, TP 3.6 g/dl, Alb 1.4 g/dl,
More informationSample2 g/dl Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl
( ) Sample2 g/dl 10 9 8 7 6 Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl 117 5.92 0.09 1.6 118 5.92 0.10 1.6 7 5.77 0.14 2.4 118 8.28 0.15 1.8 118 8.28 0.15 1.8 7 7.26 0.46 6.4 119 119 6.84 7.10 0.11 0.11
More informationM1 TSH T 3 T 4 2 T 1 2 Plummer 3 TSH TSH K 5 7 TSH TSH Plummer TSH TSH TSH TSH T 4 T 3 TSH T 4 T 3 TSH TSH or Plummer Plummer or a) 1. 2. 3. b) 1. T 4 T 3 2. TSH 0.1 U/ml 3. TSH TRAb TSAb 4. 1) a) 1
More information2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,
24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998
More information37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
More information2.7.6 MJR a MRI CT b 2 Beecham r-afs mg/ mg/ Gn-RH 742
MJR-35 34 1 1 a MRICT b 2Beecham r-afs 3 4 20 4 mg/ 20 40 5 6 2 1 2 3 44 mg/ 5 6 7 8 4 Gn-RH 742 9 10 11 12 1 20 60 1 1MJR-351 mg/ 0.25 2 Lot. No. 2MJR-352 mg/ 1 1 Lot. No. 3MJR-354 mg/ 1 2 Lot. No. 2
More informationデスフルラン
デスフルラン時代の周術期管理 岡山大学麻酔科蘇生科森松博史 デスフルランの特徴!!! 岡山大学での現状 本日のお話 デスフルランの特徴 3 Eger et al. Anesth Analg 1998; 86: 414-21 デスフルランの特徴 2 つのメタアナリシス 2005 Macario et al. Am J Health Syst Pharm!! 2010 Dexter et al.
More information/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg
17 2005/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 32 5/8 36.1 :90 /:114/64 mmhg 166.2 cm64.3 kg 3.9 g/dl 1.6 g/dl 382 mg/dl 408 mg/dl
More information日本呼吸器学会雑誌第44巻第1号
β β l β β Table1 Laboratorydataonadmission Hematology WBC 9,910/μl neut 72.4% lym 20.2% eos 0.9% mon 6.1% baso 0.4% RBC 491 10 4 /μl Hb 16.8g/dl Ht 48.3% PLT 29.8 10 4 /μl ESR 3mm/hr Biochemistry TP Alb
More information高脂血症の検査
35 30 Buffy coatbuffy coat EDTA Na Na Ca RBC Hb Ht WBC Plt ESR TP Alb CRP GOTGPTLDH BUN Cre UA HbA1C TC TG NaKClCaPFe B12 36 RBC 410530 /μl 380480 /μl Hb 13.517.6g/dL 11.315.2g/dL Ht 3648% 3443% MCV MCH
More information1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
More informationuntitled
- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - - 30 -
More information日本呼吸器学会雑誌第48巻第6号
Fig.1 Cutaneousfindingsandpathologicalfindingsofatransbronchiallungbiopsy(TBLB)andlichenifiedeczemaoftherightforearm.Thepatienthadlichenifiedeczemaonhisextremitiesandbodytrunk (1a:rightforearm,1b:leftthigh).Therewasinfiltrationoftheinflammatorylymphocytes,edemaandabrasioninthetype2alveolarepithelium
More information慈大呼吸器_25-1_02T_CS5.indd
ISSN 0919-6870. Jikei Journal of Chest Diseases Jikei University Chest Diseases Research Association 82 1 1 1 1 1 1 1 1 2 1 2 74 2010 2 2011 8 12 2012 1 17 1 20 1 28 CT 5 / 50 2011 8 2 / 1200 mg/2x 40
More informationPowerPoint プレゼンテーション
施設別登録件数と BRCA1/2 遺伝子検査の結果 施設名登録者対象者非対象者家系数 BRCA 受検者 BRCA1 陽性 BRCA2 陽性 他施設重複登録 昭和大学病院 946 225 721 195 227 34 20 2 聖路加国際病院 1691 440 1251 417 443 43 38 2 がん研有明病院 1039 248 791 198 262 48 45 4 星総合病院 259 52
More informationC033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %
2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up
More information九州支部卒後研修会症例
血液検査研修会 ( 第 25 回 ) 検査の異常から探る! 造血器腫瘍へのアプローチ 症例提示 症例 1~8 - 症例発表者 - 症例 1 藤崎恵熊本医療センター 症例 2 荒木敏造浜の町病院 症例 3 古城剛鹿児島大学病院 症例 4 佐々木高太郎都城健康サービスセンター 症例 5 矢田佳愛 大分県立病院 症例 6 下田博臣 健康保険諫早総合病院 症例 7 堤陽子 佐賀県医療センター好生館 症例 8
More information72 20 Ope / class Alb g/ cm 47.9kg : /min 112/60m
72 20Ope 68 69 2006 4 50 20 / 52 2006 4 1 2006 4 4 24 class 699.4 5 2 5 23 6 6 15 6 19 6 16 Alb2.03+ 7.5g/ 6 21 153.5cm 47.9kg : 36.7 89/min112/60mmHg (-) (-)S1 S2 S3(-) S4(-) - - 6 15 (+) TP4.9g/dl Alb2.0g/
More information03J_sources.key
Radiation Detection & Measurement (1) (2) (3) (4)1 MeV ( ) 10 9 m 10 7 m 10 10 m < 10 18 m X 10 15 m 10 15 m ......... (isotope)...... (isotone)......... (isobar) 1 1 1 0 1 2 1 2 3 99.985% 0.015% ~0% E
More information2 W.T T.S. 70 2 1 238 WBC7400/µl, RBC 386 10 4 /µl, Hb 11.6 g/dl, Ht 36.2%, PLT 25 10 4 /µl AST 19 IU/l, ALT 11 IU/l, LDH 182 IU/l, BUN 15 mg/dl, Cr 0.54 mg/dl, CRP6.83 mg/dl, RF 353.9IU/ml, CCP 28.0IU/ml
More information21 70.9 22 62.9 22 90 80 60 40 23 58 17 42 31 77.5 9 22.5 1 n 40 40 0 2 2 5.0 50 0 3 3 7.5 60 3 12 15 37.5 70 12 5 17 42.5 80 1 1 2 5.0 90 1 0 1 2.5 4
462015 Nagoya community school for health Think health scientifically : the life style and the health condition of seminar participants Hisae USAMI 21 36 67 1/3 21 21 21 1 23 6 68.2 91 43 70 42.56037.5
More information1 1 H Li Be Na M g B A l C S i N P O S F He N Cl A e K Ca S c T i V C Mn Fe Co Ni Cu Zn Ga Ge As Se B K Rb S Y Z Nb Mo Tc Ru Rh Pd Ag Cd In Sn Sb T e
No. 1 1 1 H Li Be Na M g B A l C S i N P O S F He N Cl A e K Ca S c T i V C Mn Fe Co Ni Cu Zn Ga Ge As Se B K Rb S Y Z Nb Mo Tc Ru Rh Pd Ag Cd In Sn Sb T e I X e Cs Ba F Ra Hf Ta W Re Os I Rf Db Sg Bh
More information第 14 回血管病理研究会 日時 : 平成 20 年 10 月 10 日 ( 土 ) 会場 : 佐賀大学医学部臨床大講堂 3208 号室会長 : 徳永藏 ( 佐賀大学医学部病因病態科学講座 ) CRP MPO-ANCA 125IU/l CT mpa
第 4 回血管病理研究会 日時 : 平成 20 年 0 月 0 日 ( 土 ) 会場 : 佐賀大学医学部臨床大講堂 3208 号室会長 : 徳永藏 ( 佐賀大学医学部病因病態科学講座 ). 67 2008 CRP MPO-ANCA 25IU/l 009 2 CT mpa GCA PSL 50 mg CRP MPO-ANCA mpa GCA 4 mpa ovarlap 2 TLR 2 2. 対象 方法
More information) Meropenem Chemotherapy (Tokyo) ) panipenem/betamipron Chemotherapy (Tokyo) ) Meropenem Chemotherapy (Toky
2.7 2.7.5 1) 199846410-437 2) UTI ( )UTI ( 3 )Chemotherapy (Tokyo) 1986 34408-441 3) () 199745762-778 4) 1992 5) 199543 6) Chemotherapy (Tokyo) 199139687-689 7) Imipenem/Cilastatin sodium (MK-0787/MK-0791)
More information36 th IChO : - 3 ( ) , G O O D L U C K final 1
36 th ICh - - 5 - - : - 3 ( ) - 169 - -, - - - - - - - G D L U C K final 1 1 1.01 2 e 4.00 3 Li 6.94 4 Be 9.01 5 B 10.81 6 C 12.01 7 N 14.01 8 16.00 9 F 19.00 10 Ne 20.18 11 Na 22.99 12 Mg 24.31 Periodic
More informationmg 8 mg X Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD
31 1 15 20 2016 15 3 65 5 mg 8 mg 10 15 201X 7 1 11 15 Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD AKI HD 2004 48 Acute Kidney Injury AKI 48 Cr 0.3 mg/dl
More informationCRA3689A
AVIC-DRZ90 AVIC-DRZ80 2 3 4 5 66 7 88 9 10 10 10 11 12 13 14 15 1 1 0 OPEN ANGLE REMOTE WIDE SET UP AVIC-DRZ90 SOURCE OFF AV CONTROL MIC 2 16 17 1 2 0 0 1 AVIC-DRZ90 2 3 4 OPEN ANGLE REMOTE SOURCE OFF
More informationMicrosoft Word - 第2回海外勤務健康管理抄録の表紙他.doc
第 2 回 海 外 勤 務 者 健 康 管 理 研 修 会 平 成 19 年 3 月 10 日 ( 土 ) (14 時 ~17 時 ) ( 独 ) 労 働 者 健 康 福 祉 機 構 大 阪 労 災 病 院 管 理 棟 3F 大 ホール 591-8025 大 阪 府 堺 市 北 区 長 曾 根 町 1179 番 地 の3 共 催 ( 社 ) 大 阪 府 医 師 会 ( 社 ) 日 本 産 業 衛 生
More information土壌の観察・実験テキスト −土壌を調べよう!−
( ) 2006 7 20 i 21 1962 1969 1987 1992 2005 65 1972 1977 1997 1977 1998 1982 1998 2002 2004 2005 SPP 1999 ii 1 g cm m 6378km ( ) 4.2, 4.3 5.1 7.1 8.1 4.1 7.3, 7.4 7.1 1 2 7.1 8.2 2 5 6 1, 2 2.3 4.2, 4.3
More information1996 papilloma virus 2001 Bowen AIHA PSL1mg/kg BMA PRCA parvovirus B19 PVB19 DNA PCR PV IgM 4 PVB19 PRCA MAP PVB19 DNA DNA PR
1996 papilloma virus 2001 Bowen2002 12 2003 2 2002 9 10 AIHA PSL1mg/kg BMAPRCA parvovirus B19 PVB19 DNA PCR PV IgM 4PVB19 PRCA MAPPVB19DNA DNA PRCA IVIG;20 50g/ IVIG PVB19AIHA steroid 15 20mg/day 2003
More information2 章 +αの 情 報 に 着 目 する! 1 血 球 算 定 検 査 結 果 2 生 化 学 検 査 結 果 手 がかりに 乏 しいのも+α 1 症 例 をみてみよう! 1 60 吉 見 祐 輔 1 2 11percutaneous coronary intervention PCI104 38.
2 章 +αの 情 報 に 着 目 する! 1 血 球 算 定 検 査 結 果 2 生 化 学 検 査 結 果 手 がかりに 乏 しいのも+α 1 症 例 をみてみよう! 1 60 吉 見 祐 輔 1 2 11percutaneous coronary intervention PCI104 38.1 130 75mmHg 83 16 SpO 297 1 3 WBCL RBC10 4 L Hb g
More information日本目録規則1987年版改訂2版第2章図書改定案
2.0.1 2.0.2 2.0.3 2.0.4 2.0.5 2.0.6 2.1.1 2.1.2 2.1.3 2.1.4 2.1.5 2.2.1 2.2.2 2.2.3 2.2.4 2.4.1 2.4.2 2.4.3 2.4.4 2.5.1 2.5.2 2.5.3 2.5.4 2.6.1 2.6.2 2.6.3 2.6.4 2.6.5 ISSN 2.6.6 2.6.7 2.7.1 2.7.2 2.7.3
More information表紙/151708H
! " # $ % & ' ( ) ! #! $! " % & " ' " # * + $ %, &! & ', '! " # $ (! " # $ )! " # $ !!$ "! " # $ #! " # $ $! " # $ %! " # $ ! " # " 1 $ 2 " $ % 3 & % ' ( 4 ( ) * ' + 5, -. 6 / 0 0 +, 1 -. 2 3 /! /!%!!
More information001-029_”÷’X
54 2012 1 29 Kimori Daisuke Kamijo Takashi Takahashi Akira 1993 19951997 2001 10 1993 1999 1992 54 2012 1993 20 LDH BUNCRE UA CPK GOT CPK LDH UA CPK LDH UA CPK 1989 2001 2000 1989 1995 2003 2005 1989 54
More information( )
18 10 01 ( ) 1 2018 4 1.1 2018............................... 4 1.2 2018......................... 5 2 2017 7 2.1 2017............................... 7 2.2 2017......................... 8 3 2016 9 3.1 2016...............................
More information活用ガイド (ソフトウェア編)
ii iii iv NEC Corporation 1998 v vi PA RT 1 vii PA RT 2 viii PA RT 3 PA RT 4 ix P A R T 1 2 3 1 4 5 1 1 2 1 2 3 4 6 1 2 3 4 5 7 1 6 7 8 1 9 1 10 1 2 3 4 5 6 7 8 9 10 11 11 1 12 12 1 13 1 1 14 2 3 4 5 1
More information物理化学I-第12回(13).ppt
I- 12-1 11 11.1 2Mg(s) + O 2 (g) 2MgO(s) [Mg 2+ O 2 ] Zn(s) + Cu 2+ (aq) Zn 2+ (aq) + Cu(s) - 2Mg(s) 2Mg 2+ (s) + 4e +) O 2 (g) + 4e 2O 2 (s) 2Mg(s) + O 2 (g) 2MgO(s) Zn(s) Zn 2+ (aq) + 2e +) Cu 2+ (aq)
More information温泉の化学 1
H O 1,003 516 149 124 2,237 1974 90 110 1km 2,400 ( 100 Mg 200 (98 ) 43,665 mg 38,695 mg 19,000 mg 2000 2000 Na-Ca-Cl 806 1970 1989 10 1991 4 ph 1 981 10,000 1993... (^^; (SO_4^{2-}) " " 1973-1987 1970
More information肝臓病教室201207v2配布用.pptx
24 7 28 5 C C C C 11 1 vs 2 vs 1 0 1 600-1000mg 3-5/ 24,48 2448 12 1 1500-2250mg 6-9/ () 1 600-1000mg 3-5/ 0 24 88.1% 0 20 40 60 80 100 C ALT, GPT 30 34.4% ALT, GPT 0 20 40 60 80 100 2 , 2 3 1 1-100% 0
More information/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) ( 10 2 %) (g/l) ( 10 2 %) 0.75 ( 10 2 %) 0.15 ( 10 2 %)
/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) (10 2 %) 0.32 0.55 0.37 0.55 95 165 115 185 (10 2 %) 0.75 (10 2 %) 0.15 (10 2 %) 0.10 10 2 % 0.10 10 2 % 0.15 10 2 % 0.10 Bands(10 2 %) 0.10 (10 9 75
More informationッ ー ー ー() () 2.5 () () 21 1) -1 2) -2 10 m 5 7 23 6 1)2) 3) -1-2 H23.4.25 -15-20 4 75 5 1) -1 (5) (3) (3) (2) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) 1) ( 23 6 8 ) 2) 22 3)
More information_03大山.indd
36, 13-19, 2016 2 24 24 6 12 1% 1 DIC 2 1 40 30 0 0 IVM - ICSI - ; in vitro mturtion - intrcytoplsmic sperm injection 32 5 mm 37 3 1,300 g 7 H 10.1 g/dl 10 ER 104/69 mmhg 78 / 1 FBG 1 100 ml FFP 300 ml
More informationSARS HIV/AIDS n = 672; % 5% 2% 8% 16% 43% 20%
SARS HIV/AIDS n = 672; 20074 20108 6% 5% 2% 8% 16% 43% 20% 1999 2008 HIV/AIDS B A 0% 50% 100% 1049 552 17 186 867 431 739 3847 332 7556 102 2420 3648 449 802 2709 31774 1286 13651 1611 207 95 8 162 667
More informationDiovNT
厚生労働科学研究費補助金 ( 難治性疾患等克服研究事業 ) 分担研究報告書 わが国の Cystic ˆbrosis 患者における CFTR 遺伝子変異の特徴 研究報告者石黒洋名古屋大学総合保健体育科学センター教授 共同研究者中莖みゆき, 山本明子, 近藤志保 ( 名古屋大学総合保健体育科学センター健康栄養医学 ) 藤木理代, 北川元二 ( 名古屋学芸大学管理栄養学部管理栄養学科 ), 洪繁 ( 慶應義塾大学医学部システム医学
More information橡Taro11-報告書0.PDF
Research Center RC 2001 5-1- RC RC NHK -2- -3- 00/12/16 RC 01/01/07 RC 01/01/21 1 13 01/02/11 2 9 01/02/10 01/02/14 01/02/19 01/02/25 3 7 01/03/10 4 8 01/03/23 5 8 01/04/29 2001/01/07-4- -5- RC 1990 RC
More information387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
386 B B () () ( ) ( ) ( ) 387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 388 ( ) ( ) ( ) 389 ( ) 2 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 390 ( ) ( ) ( ) () () ( ) Hot flush 391 ( ) ( ) ( ) 392 ( ( )
More informationuntitled
DiBartola SP DiBartola SP 1987 Elliott Elliott J 1998 Elliott J 2000 Elliott J 2003 Part 1 24 0.75 70 1.3 1.3 2.0 1/2 2 6 1/2 22 18 Part 2003 Dr Chew 1 2 2 3 Part Cre Cre 1 Part Cre 2% 0.1ml/kg 0.3ml/kg
More information20-121
20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150
More information5 CSF 6 CSF 7 CSF CSF CDV CDV GFAP CSF Pandy test NSE MBP LDH mu/ml 0-5 /µl AST mu/ml CK mu/ml <25 mg/dl<45 mg/dl GLU
CT MRI CSFCSF CSF CSF CSF CSF CSF (cisternal puncture) CSF 20-23G 90 (20-23G) : CSF
More informationindd
18 61 1 2011 症例報告 2010 5 13 2010 12 20 A Case of Varicella with Severe Back Pain in a Patient with Systemic Lupus Erythematosus RIE SAITO, KIORI YANO, FUMIKO KATSUSHIMA, HARUYO IWADATE, HIROKO KOBAYASHI,
More information[] 1
0 [] 1 [] 2 [] 2010 22 0% 20% 40% 60% 80% 100% 15.4 65.2 10.8 8.6 12,000 2010 22 2020 32 2030 42 2040 52 2015 27 14.3 63.3 12.3 10.1 10,000 2020 32 13.2 63.0 11.9 11.9 8,000 2025 37 12.3 62.9 10.6 14.2
More informationNSIPとUCTD(HP用).ppt
NSIP (- NSIP) (Non-) NSIP (Kinder) Retrospective () (Non-) (Kinder) 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 1. 2. RA 3. Scl-70 4. SS-ASS-B 5. Jo-1 6. (>), CRP NSIP 62 6PM/DM* 9 47 *PM/DM: Polymyositis/dermatomyositis
More information小児感染免疫第25巻第2号
Vol. 25No. 2145 1,2 1 1 1 1 2 2 2 TFLX 9 TFLX 450 mg16.6 mgkg TFLX 30 kg TFLX 2009 10 TFLX 1 1 2 3,4 TFLX 9 22 6 18 19 TFLX 450 mg150 mg 1 1 1 3 16.6 mgkg 20 20 0 21 3 135.0 cm0.1 S.D. 27.0 kg0.8 S.D.
More information1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載
1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載のない限り 熱容量を考慮した空き容量を記載しております その他の要因 ( 電圧や系統安定度など ) で連系制約が発生する場合があります
More information051
Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 389( 15 ) 1. MDS collagenase 2. 1 3. 4. / 390( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 Aug. 4 4 2004 10 2 1 NTT Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS
More information2 Zn Zn + MnO 2 () 2 O 2 2 H2 O + O 2 O 2 MnO 2 2 KClO 3 2 KCl + 3 O 2 O 3 or 3 O 2 2 O 3 N 2 () NH 4 NO 2 2 O + N 2 ( ) MnO HCl Mn O + CaCl(ClO
1 [1]. Zn + 2 H + Zn 2+,. K Ca Na Mg Al Zn Fe Ni Sn Pb H Cu Hg Ag Pt Au H (H + ),,. [2] ( ) ( ) CO 2, S, SO 2, NH 3 () + () () + () FeS Fe S ( ) + ( ) ( ) + ( ) 2 NH 4 Cl + Ca(OH) 2 Ca O + 2 NH 3,.,,.,,.,.
More informationph
14 12 9 3 4 1 7 1.1..................... 7 1.2 ph............................ 9 1.2.1...... 9 1.2.2.... 12 4.4..... 55 1.2.3 14 4.4.1......... 56 1.2.4............. 19 2 21 2.1.......... 21 2.2......................
More information200 30 984 1 1854 1713 1000 1008 ED ADL/QOL The European Working Group on Sarcopenia in Older People EWGSOP Asian Working Group for Sarcopenia AWGS D C Zhang, 2006 C Imamura, 2008 ATP Imamura, 2009 Imamura,
More information溶血性尿毒症症候群 ver 最終.pptx
Hemolytic uremic syndrome(hus) ver0130525 (HUS), Stx VT 3 3 1. ( Hb10g/dl ) 2. ( 10 /µl ) 3. ( 97.5 ) 1.5 ) (HUS) D+HUS D-HUS(aHUS) HUS ahus ( 6 HUS ( ) HUS HUS ahus O-157 9-30 HUS 15 80 5 5 10 2-3 (O-157
More information2 129-B*-006P 129-B*-007P C*-004P 129-D*-001P ADH B*-006P B*-007P C*-004P D*-001P Na
2.7.4 2.7.4.1 2.7.4.1.1 11 ADH 1 ADH 1 4 7 129-A*-003 129-B*-001 129-E*-001P 129-G*-001 129-H*-002 129-H*-004 129-H*-005 132 242 4 129-B*-004 129-C*-005P 129-H*-003 129-H*-006 44 ADH ADH 129-C*-001P 16
More information[ ] (Verschieden Wissenschaft auf Pedologie fur Geologe) (Taqumi, TuZino) Julius 2007 I. 3 II. 3 II. 1 : : : : : : : : : : : : :
[ ] (Verschieden Wissenschaft auf Pedologie fur Geologe) 2008 1 8 (Taqumi, TuZino) 2008 1 8 10 Julius 2007 I. 3 II. 3 II. 1 : : : : : : : : : : : : : : : : : : : : : : : : : : : : 3 II. 2 : : : : : : :
More information...J......1803.QX
5 7 9 11 13 15 17 19 21 23 45-1111 48-2314 1 I II 100,000 80,000 60,000 40,000 20,000 0 272,437 80,348 82,207 81,393 82,293 83,696 84,028 82,232 248,983 80,411 4,615 4,757 248,434 248,688 76,708 6,299
More informationX G P G (X) G BG [X, BG] S 2 2 2 S 2 2 S 2 = { (x 1, x 2, x 3 ) R 3 x 2 1 + x 2 2 + x 2 3 = 1 } R 3 S 2 S 2 v x S 2 x x v(x) T x S 2 T x S 2 S 2 x T x S 2 = { ξ R 3 x ξ } R 3 T x S 2 S 2 x x T x S 2
More information112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6 7 B 2 NTT 2012 6
Apr. 2013 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 111 53 8 8 1. Ph-ALL Liposomal amphotericin B 1 2. CBT MCFG L-AMBAML 2 112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6
More information2 1 7 - TALK ABOUT 21 μ TALK ABOUT 21 Ag As Se 2. 2. 2. Ag As Se 1 2 3 4 5 6 7 8 9 1 1 2 3 4 5 6 7 8 9 1 1 2 3 4 5 6 7 8 9 1 Sb Ga Te 2. Sb 2. Ga 2. Te 1 2 3 4 5 6 7 8 9 1 1 2 3 4 5 6 7 8 9 1 1 2 3 4
More informationC VECS C F M kg A E W kg I A R. R. Gkg MGD MGD MGD MGD SPKMGD MGD MGD SPK SPK MGD MMP MMP MMP kg mmhg Intrascleral prosthesis : ISPISP ISP ISP ISP ISP ISP ISP ISP ISP mm mm ISP mm min mm min ISP mm min
More information表 1 入院時検査所見 11,500L 471 L 17.0 gdl.3 L ph 7.49 PaCO 37.8 mmhg PaO 67.4 mmhg HCO 3.6 meql B E 1. meql 141 meql K 3.9 meql Cl 108 meql Ca 8.4 mgdl P 4.5
Ⅰ. 臨床編 A. 特殊な病態における輸液 1 新生児 未熟児における輸液 実践編症例検討 症例の経過と実際の輸液療法 症例 ❶ 0 主訴 分娩歴 38 4,110 g.4 SD 47.5 cm0.5 SD 3.5 cm0.5 SD 8 1 9 5 現病歴 35 mgdl 60 0 mgdl 入院時現症 150 50 37. 503 mmhg SpO 98FiO 0.1 入院時検査所見 33 mgdl
More information血糖高いのは朝食後のため検査項目 下限値上限値 単位名称 9 月 3 日 9 月 6 日 9 月 15 日 9 月 18 日 9 月 21 日 9 月 24 日 9 月 28 日 10 月 1 日 10 月 3 日 10 月 5 日 10 月 9 日 10 月 12 日 10 月 15 日 10 月
検査項目 下限値上限値 単位名称 7 月 9 日 7 月 10 日 7 月 11 日 7 月 12 日 7 月 13 日 7 月 17 日 7 月 20 日 7 月 23 日 7 月 25 日 7 月 27 日 7 月 30 日 8 月 3 日 8 月 6 日 8 月 8 日 8 月 10 日 8 月 12 日 8 月 15 日 8 月 17 日 8 月 20 日 8 月 22 日 8 月 24 日
More informationリサイクルデータブック2016
AppendixEU SDGs2159EU 21512UNEPOECD2165G7 2165 213 Appendix 1 EU 2 EU 3 215 i CONTENTS i 1 213 1 213 2 1 4 2 2 6 3 3 6 4 213 7 4 5 9 6 213 9 5 7 1 8 213 1 9 11 1 213 11 11 213 11 6 6.1 12 213 14 6.2 13
More information1 (1) vs. (2) (2) (a)(c) (a) (b) (c) 31 2 (a) (b) (c) LENCHAR
() 601 1 () 265 OK 36.11.16 20 604 266 601 30.4.5 (1) 91621 3037 (2) 20-12.2 20-13 (3) ex. 2540-64 - LENCHAR 1 (1) vs. (2) (2) 605 50.2.13 41.4.27 10 10 40.3.17 (a)(c) 2 1 10 (a) (b) (c) 31 2 (a) (b) (c)
More information05-d m-4.03
Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 51(51) ABPA(M) 1 ABPM ITCZ 2 ABPA ITCZ 3 ABPA ABPM ABPM 52(52) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb. 9 2004 3 6 4 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS
More information名称未設定-2
Contents 1 2 3 4 5 6 7 8 9 1 11 12 13 14 15 16 17 18 19 2 21 22 i 23 24 25 26 27 28 29 3 31 32 33 34 35 36 37 38 39 4 41 42 43 44 45 46 47 48 49 5 51 52 53 54 55 56 57 ii 58 59 6 61 62 63 64 65 66 67 68
More information1 2 2 ANCA pouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - ' UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, cm 61
1 2 2 ANCApouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - '03 2 3 31 UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, 3+ 4 14 156.0 cm 61.5 kg 36.9 158/92 mmhg 90 1. ANCA 2. 3. IgG4 deposit
More informationuntitled
(1) 100 100 60% (2) (3) - 1 - 1 2 3 4 100 200-2 - 1 2 3-3 - 4 5 6 7......... (1) (2) (3) 1) 2) 3) 8(5) - 4 - 0.5 27.3 3 0.05 27.30 4 0.005 Système International d'unités 7218 1 (1) Pas Pas J/molK J/(molK)
More information4_Laser.dvi
1 1905 A.Einstein 1917 A.Einstein 1954 C.H.Townes MASER Microwave Amplification by Stimulated Emission of Radiation 23.9 GHz 1.26 cm 1960 T.H.Maiman LASER Light Amplification by Stimulated Emissin of Radiation
More informationMast Cell Tumor : MCT c-kit MCT F F MCT C c-kit DNA Canine DNA Ver DNA c-kit C c 1275 A G F c.2355 G A DNA F C F C c-kit MCT c-kit DNA MCT Kiel T B kg cm T T Stage a UW25 P MDR1 B L T B L Leptospira L
More informationhttp://www.ike-dyn.ritsumei.ac.jp/ hyoo/wave.html 1 1, 5 3 1.1 1..................................... 3 1.2 5.1................................... 4 1.3.......................... 5 1.4 5.2, 5.3....................
More informationValganciclovir 1 CMV valganciclovir VGCV CMV IgM CMV-DNA CMV 34 VGCV 2 1 CMV CMV ganciclovir valganciclovir MRI cytomegaloviru
2012445559 55 Valganciclovir 1 CMVvalganciclovirVGCV 1 21 5 CMV IgM CMV-DNA CMV 34 VGCV 2 1 CMV CMV ganciclovirvalganciclovir MRI cytomegalovirus; CMV TORCH CMV 1 CMV valganciclovirvgcv 21 2 1 1 2 23 37
More information日本呼吸器学会雑誌第44巻第7号
Table1Laboratoryfindingsonadmission Hematology Serology LungFunctionTest WBC 7,410 /μl CRP 7.7mg/dl VC 3.12L(97.2%) Neut 66.4 % KL-6 777U/ml FEV1.0 2.35L(78.25%) Eosino 3.2 % PT (INR) 0.94 %DLCO 47.6 %
More information(1.2) T D = 0 T = D = 30 kn 1.2 (1.4) 2F W = 0 F = W/2 = 300 kn/2 = 150 kn 1.3 (1.9) R = W 1 + W 2 = = 1100 N. (1.9) W 2 b W 1 a = 0
1 1 1.1 1.) T D = T = D = kn 1. 1.4) F W = F = W/ = kn/ = 15 kn 1. 1.9) R = W 1 + W = 6 + 5 = 11 N. 1.9) W b W 1 a = a = W /W 1 )b = 5/6) = 5 cm 1.4 AB AC P 1, P x, y x, y y x 1.4.) P sin 6 + P 1 sin 45
More informationPROSTAGE[プロステージ]
PROSTAGE & L 2 3200 650 2078 Storage system Panel system 3 esk system 2 250 22 01 125 1 2013-2014 esk System 2 L4OA V 01 2 L V L V OA 4 3240 32 2 7 4 OA P202 MG55 MG57 MG56 MJ58 MG45 MG55 MB95 Z712 MG57
More information1) Urlne analysls 7)Serologlcal exam. 1 1)ECG W.N.L. sugar 0% CRP (-) urobillnogen N(+) RA (+) 12)Renal function albumin 3(+) ASLO (-) PSP test 15' 40
A case of membranoproliferative glomerulonephritis accompanied with hyper IgM immunodeficiency Kenichiro SHIGEMOTO, Koji WADA, Naoki HAMAGUCHI, Akira HIRABAYASHI, Shunji TOI, Koji USUI, Michiko ARITA,
More information64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () m/s : : a) b) kg/m kg/m k
63 3 Section 3.1 g 3.1 3.1: : 64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () 3 9.8 m/s 2 3.2 3.2: : a) b) 5 15 4 1 1. 1 3 14. 1 3 kg/m 3 2 3.3 1 3 5.8 1 3 kg/m 3 3 2.65 1 3 kg/m 3 4 6 m 3.1. 65 5
More informationBAANs理論に基づく保健指導プログラム暫定版
WHO 4 5 10% L- -3 RNA L - 1960-3 RNA mrna Bio Activating Advanced Nutrients BAANs BAANs BAANs BAANs L- (NO) -3 EPA, DHA) RNA RNA DNA TNF- PAI-1 ( ) BAANs 40 50% 20% 1Kg 7,000Kcal 50Kcal 11 50Kcal
More informationindd
60 4 2010 197 症例報告 1 1 1 2 2 2 2 3 4 1 2 3 4 2010 7 27 2010 9 24 Case of a Young Adult Male Complicated with Ischemic Colitis EMI OGATA 1, TAKERU WAKATSUKI 1, HIROAKI SAKAMOTO 1, NATSUMI SAKAMOTO 2, OSAMU
More information